Savastano Maria Cristina, Crincoli Emanuele, Toto Lisa, Grassi Maria Oliva, Chiosi Flavia, Savastano Alfonso, Rizzo Clara, Mastropasqua Rodolfo, Boscia Francesco, Rizzo Stanislao
Ophthalmology Unit, "Fondazione Policlinico Universitario A. Gemelli IRCCS", 00168 Rome, Italy.
Department of Head and Neck Medicine, Catholic University of "Sacro Cuore", 00168 Rome, Italy.
Diagnostics (Basel). 2024 Nov 25;14(23):2653. doi: 10.3390/diagnostics14232653.
To report the occurrence of the regression of the flow signal from the neovascular network in macular neovascularizations (MNVs), developing in the context of age-related macular degeneration (AMD), treated with faricimab in a treat-and-extend regimen.
Eyes affected by AMD-related MNV and treated with faricimab intravitreal injections in a treat-and-extend (TE) regimen were consecutively retrospectively screened in five specialized retina centers. Changes in neovascular network characteristics during the course of the treatment were analyzed. The availability of high-quality optical coherence tomography angiography (OCTA) at the beginning of the treatment and at the regression of the MNV was necessary for inclusion. According to greatest linear diameter (GLD) changes during treatment, eyes were divided into three groups: a complete regression (CR) group, a partial remission (PR) group (a reduction of at least 50% of the GLD from baseline to last follow-up), and a stable group (stable/showing a reduction lower than 50% of the GLD from baseline to follow up).
One hundred and ten (110) eyes were included. The CR group was composed of 12 eyes (10.9%), while the PR group represented 60.9% of the study population. CR occurred after a mean of 6.0 ± 1.4 months, ranging from 4 to 8 months. Time to regression was significantly lower in eyes naïve to treatment before the study compared with the others ( = 0.022). A significantly lower baseline GLD was detected in the CR group (1292.2 ± 195.6 μm) compared with the PR group (1324.6 ± 135.6 μm) and the stable group (1412.5 ± 110.9 μm) (omnibus = 0.003).
Complete regression of the flow signal from the MNV neovascular network documented with OCTA may occur during TE regimens with faricimab. In treatment-naïve eyes, regression occurs earlier during the treatment.
报告在年龄相关性黄斑变性（AMD）背景下发生的黄斑新生血管（MNV）中，采用faricimab治疗并延长给药方案时，新生血管网络血流信号消退的情况。
在五个专业视网膜中心对患有AMD相关MNV并采用faricimab玻璃体腔注射治疗并延长给药方案的眼睛进行连续回顾性筛查。分析治疗过程中新生血管网络特征的变化。纳入标准为治疗开始时和MNV消退时需有高质量的光学相干断层扫描血管造影（OCTA）。根据治疗期间最大线性直径（GLD）的变化，将眼睛分为三组：完全消退（CR）组、部分缓解（PR）组（从基线到最后一次随访GLD至少减少50%）和稳定组（稳定/从基线到随访GLD减少低于50%）。
共纳入110只眼睛。CR组有12只眼睛（10.9%），而PR组占研究人群的60.9%。CR平均发生在6.0±1.4个月后，范围为4至8个月。与其他眼睛相比，研究前未接受过治疗的眼睛消退时间显著更短（P = 0.022）。与PR组（1324.6±135.6μm）和稳定组（1412.5±110.9μm）相比，CR组的基线GLD显著更低（1292.2±195.6μm）（总体P = 0.003）。
在faricimab治疗并延长给药方案期间，OCTA记录的MNV新生血管网络血流信号可能会完全消退。在未接受过治疗的眼睛中，消退在治疗期间更早发生。
